EC Number   |
Inhibitors |
Structure |
|---|
    2.7.2.1 | acetyl phosphate |
product inhibition |
   |
| 2.7.2.1 | adenosine 5'-(gamma-thio)triphosphate |
- |
|
| 2.7.2.1 | ADP |
- |
|
| 2.7.2.1 | ADP |
inhibition by preincubation with MgCl2, ADP, AlCl3, NaF, and acetate. When MgCl2, ADP, and acetate are omitted from the preincubation mixture, there is no detectable loss of activity; inhibition of acetate kinase by preincubation with MgCl2, ADP, AlCl3, NaF, and acetate (all of the components are necessary for maximum inhibition). The transition state analog, MgADP-aluminum fluoride-acetate, forms an abortive complex in the active site |
|
| 2.7.2.1 | ADP |
competitive inhibition; competitive inhibition |
|
| 2.7.2.1 | AlCl3 |
inhibition by preincubation with MgCl2, ADP, AlCl3, NaF, and acetate. When MgCl2, ADP, and acetate are omitted from the preincubation mixture, there is no detectable loss of activity; inhibition of acetate kinase by preincubation with MgCl2, ADP, AlCl3, NaF, and acetate (all of the components are necessary for maximum inhibition). The transition state analog, MgADP-aluminum fluoride-acetate, forms an abortive complex in the active site. Protection from inhibition by a non-hydrolyzable ATP analog or acetylphosphate. Preincubation of acetate kinase with MgCl2, AlCl3, NaF, acetate, and either IDP, UDP, or CDP in place of ADP results in almost complete inhibition of activity |
|
| 2.7.2.1 | ATP-gamma-S |
non-hydrolyzable inhibitor |
|
| 2.7.2.1 | Bromoacetate |
- |
|
| 2.7.2.1 | Ca2+ |
less than 1% residual activity at 1.3 mM |
|
| 2.7.2.1 | CDP |
preincubation of acetate kinase with MgCl2, AlCl3, NaF, acetate, and either IDP, UDP, or CDP in place of ADP results in almost complete inhibition of activity |
|
